University of Utah Hospital and Clinic
Welcome,         Profile    Billing    Logout  
 11 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bowlus, Christopher L
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
Aabakken, Lars
FARE, NCT05504434: Performance of a Single-use Gastroscope (aScope Gastro) for Esophagogastroduodenoscopy

Completed
N/A
60
Europe
Single-use gastroscope
Erasmus Medical Center, Maag Lever Darm Stichting, Ambu A/S
Gastroscopy, Esophagogastroduodenoscopy, Equipment Design, Equipment Contamination / Prevention & Control, Cross Infection / Prevention & Control, Disposable Equipment, Infection Control / Methods
12/23
12/23
Ponsioen, Cyriel Y
MALD, NCT05359497: Value of MRCP+ And Liver Multiscan in the Management of Dominant Strictures in Primary Sclerosing Cholangitis

Not yet recruiting
N/A
50
NA
Liver Multiscan sequences baseline, MRCP+ analysis baseline, Liver Multiscan analysis baseline, LMS, MRI liver with MRCP, Liver Multiscan sequences follow-up, MRCP+ analysis follow up, Liver Multiscan analysis follow up
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Perspectum
PSC, MRI
05/23
12/23
CATCH-IT, NCT05462093: Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis

Not yet recruiting
N/A
200
NA
Liver Multiscan sequences, Liver Multiscan analysis, LMS, MRCP+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Perspectum
Primary Sclerosing Cholangitis
07/28
07/29
McDonough, Stephanie
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25

Download Options